Inspire Medical Systems, Inc. to Report Second Quarter 2022 Financial Results on August 2, 2022

Rhea-AI Summary

Inspire Medical Systems (NYSE: INSP) will announce its financial results for Q2 2022 on August 2, after market hours. A conference call is scheduled for 5:00 p.m. ET to discuss these results and recent business developments. The call can be accessed through a registration link, and a simultaneous webcast will be available on Inspire's Investor Relations page. Inspire specializes in innovative, minimally invasive solutions for obstructive sleep apnea, notably its FDA-approved Inspire therapy, which offers treatment for moderate to severe cases.

Positive

• Inspire therapy is the first FDA-approved neurostimulation technology for obstructive sleep apnea.

Negative

• None.

MINNEAPOLIS, July 05, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the second quarter 2022 after the close of trading on Tuesday, August 2. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

To access the call, please use the following link: Inspire’s Q2 2022 earnings call. After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call. 

A simultaneous webcast of the call will be accessible via the Investor Relations page of the Inspire’s website at www.inspiresleep.com. For those not planning to ask a question of management, the Company recommends listening via the webcast.

Following the call, a replay will be available on the Company's Investor Relations website approximately two hours after the event and archived on the site for two weeks.

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact:
Bob Yedid
LifeSci Advisors
inspire@lifesciadvisors.com
646-597-6989

FAQ

When will Inspire Medical Systems release Q2 2022 financial results?

Inspire Medical Systems will release Q2 2022 financial results on August 2, 2022.

What time is the Inspire Medical Systems Q2 earnings call?

The earnings call will take place at 5:00 p.m. ET on August 2, 2022.

Where can I listen to Inspire Medical Systems' Q2 earnings call?

The earnings call can be accessed via a registration link and will also be available as a webcast on Inspire's Investor Relations page.

What is Inspire Medical Systems known for?

Inspire Medical Systems is known for its innovative solutions for obstructive sleep apnea, particularly the Inspire therapy, the first FDA-approved neurostimulation technology for this condition.